Progress in conversion therapy of liver metastasis in initially unresectable colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2023.04.011

Abstract

Abstract:

Colorectal cancer is the second largest cause of cancer-related death in the world, and ranks as the third most common malignant tumor in the world. Approximately 25% of patients present with colorectal liver metastases(CRLM) at first diagnosis, and surgical treatment is often considered necessary for the potential long-term survival of patients with CRLM. The median overall survival (OS) of patients who achieved R0 resection in CRLM was 42 months, and the 5-year survival rate was 35%~40%. The initial resectable rate is less than 20%. Therefore, surgical resection of initial unresectable CRLM after conversion therapy will significantly improve the prognosis of patients with CRLM. In this review, we introduce the latest literature on initial unresectable CRLM conversion therapy,and discuss the advances in diagnosis, treatment methods and therapeutic effects, so as to guide clinical practice.

Key words: Colorectal neoplasms, Liver metastases, Transformation therapy

Yuxing Liu, Chenming Liu, Jinlin Du. Progress in conversion therapy of liver metastasis in initially unresectable colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(04): 337-341.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2023.04.011

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2023/V12/I04/337

References 41

[1]	Global Burden of Disease Cancer C, Fitzmaurice C, Abate D, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study [J]. JAMA Oncol, 2019, 5(12): 1749-1768.
[2]	Giannis D, Sideris G, Kakos CD, et al. The role of liver transplantation for colorectal liver metastases: A systematic review and pooled analysis [J]. Transplant Rev (Orlando), 2020, 34(4): 100570.
[3]	Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer [J]. Ann Gastroenterol Surg, 2019, 3(1): 50-56.
[4]	Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases - a population-based study on incidence, management and survival [J]. BMC Cancer, 2018, 18(1): 78.
[5]	Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors [J]. Clin Epidemiol, 2012, 4: 283-301.
[6]	Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy [J]. J Clin Oncol, 2009, 27(22): 3677-3683.
[7]	Benson AB, Venook AP, Al-hawary MM, et al. Colon Cancer, Version 2.2021, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2021, 19(3): 329-359.
[8]	Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer [J]. Ann Oncol, 2016, 27(8): 1386-1422.
[9]	Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J]. Ann Surg, 1996, 224(4): 509-520; discussion 20-22.
[10]	Cai GX, Cai SJ. Multi-modality treatment of colorectal liver metastases [J]. World J Gastroenterol, 2012, 18(1): 16-24.
[11]	Basso M, Dadduzio V, Ardito F, et al. Conversion chemotherapy for technically unresectable colorectal liver metastases: a retrospective, STROBE-compliant, single-center study comparing chemotherapy alone and combination chemotherapy with cetuximab or bevacizumab [J]. Medicine (Baltimore), 2016, 95(20): e3722.
[12]	Leung U, Gönen M, Allen PJ, et al. Colorectal cancer liver metastases and concurrent extrahepatic disease treated with resection [J]. Ann Surg, 2017, 265(1): 158-165.
[13]	Fakih MG. Metastatic colorectal cancer: current state and future directions [J]. J Clin Oncol, 2015, 33(16): 1809-1824.
[14]	Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study [J]. J Clin Oncol, 2004, 22(2): 229-237.
[15]	Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis [J]. J Natl Cancer Inst, 2011, 103(1): 21-30.
[16]	Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest [J]. J Clin Oncol, 2007, 25(13): 1670-1676.
[17]	Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial [J]. Lancet, 2008, 371(9617): 1007-1016.
[18]	Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases [J]. Br J Cancer, 2007, 97(8): 1035-1039.
[19]	Adam R, Wicherts DA, De Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? [J]. J Clin Oncol, 2009, 27(11): 1829-1835.
[20]	Saltz LB, Clarke S, Díaz-rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study [J]. J Clin Oncol, 2008, 26(12): 2013-2019.
[21]	Giantonio BJ, Levy DE, O'dwyer PJ, et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200 [J]. Ann Oncol, 2006, 17(9): 1399-1403.
[22]	Okines A, Puerto OD, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial [J]. Br J Cancer, 2009, 101(7): 1033-1038.
[23]	Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection [J]. Ann Oncol, 2011, 22(9): 2042-2048.
[24]	Cremolini C, Loupakis F, Antoniotti C, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest [J]. Ann Oncol, 2015, 26(6): 1188-1194.
[25]	Martin RC2nd, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis [J]. Cancer, 2015, 121(20): 3649-3658.
[26]	Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases [J]. J Clin Oncol, 2013, 31(16): 1931-1938.
[27]	Cheng AL, Cornelio G, Shen L, et al. Efficacy, tolerability, and biomarker analyses of once-every-2-weeks cetuximab plus first-line FOLFOX or FOLFIRI in patients with KRAS or all RAS wild-type metastatic colorectal cancer: the phase 2 APEC study [J]. Clin Colorectal Cancer, 2017, 16(2): e73-e88.
[28]	Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials [J]. Eur J Cancer, 2012, 48(10): 1466-1475.
[29]	Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial [J]. Lancet Oncol, 2010, 11(1): 38-47.
[30]	Carrato A, Abad A, Massuti B, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) [J]. Eur J Cancer, 2017, 81: 191-202.
[31]	Diaz L AJr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study [J]. Lancet Oncol, 2022, 23(5): 659-670.
[32]	Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers [J]. Nat Med, 2020, 26(4): 566-576.
[33]	Demisse R, Damle N, Kim E, et al. Neoadjuvant immunotherapy-based systemic treatment in MMR-deficient or MSI-High rectal cancer: case series [J]. J Natl Compr Canc Netw, 2020, 18(7): 798-804.
[34]	Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 361-375.
[35]	Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study [J]. Anticancer Res, 2012, 32(4): 1387-1395.
[36]	Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study [J]. J Clin Oncol, 2002, 20(6): 1499-1505.
[37]	Lévi FA, Boige V, Hebbar M, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV [J]. Ann Oncol, 2016, 27(2): 267-274.
[38]	Garlipp B, Gibbs P, Van Hazel GA, et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial [J]. Br J Surg, 2019, 106(13): 1837-1846.
[39]	Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases [J]. Br J Cancer, 2010, 103(3): 324-331.
[40]	Van Lienden KP, Van Den Esschert JW, De Graaf W, et al. Portal vein embolization before liver resection: a systematic review [J]. Cardiovasc Intervent Radiol, 2013, 36(1): 25-34.
[41]	Adam R, Laurent A, Azoulay D, et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors [J]. Ann Surg, 2000, 232(6): 777-785.

Please choose a citation manager

Content to export